Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. The Dow Jones Industrial Average ( ^DJI) is trading down 39.0 points (-0.3%) at 14,520 as of Wednesday, Mar 27, 2013, 11:35 a.m. ET. During this time, 191.8 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 618.1 million. The NYSE advances/declines ratio sits at 1,021 issues advancing vs. 1,843 declining with 151 unchanged.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Dow component leading the way higher looks to be Johnson & Johnson (NYSE: JNJ), which is sporting a 39-cent gain (+0.5%) bringing the stock to $81.24. Volume for Johnson & Johnson currently sits at 4.7 million shares traded vs. an average daily trading volume of 9.6 million shares. Johnson & Johnson has a market cap of $222.87 billion and is part of the health care sector and drugs industry. Shares are up 15.3% year to date as of Tuesday's close. The stock's dividend yield sits at 3.1%. Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The company has a P/E ratio of 20.6, above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.